Drug That Lowers Resting Heart Rate Be... (lar medicine Weill Cornell Medical Colle...)

(Date:12/4/2008)... SEATTLE, Dec. 5 Cell T...q and MTA: CTIC) today announced that that its Boa...Auction" tender offer to,purchase a portion or al...) as,follows: , , -- 4% Convertible Senior...ible Senior Notes due 2011, -- 6.75% Convertib...

(Date:12/4/2008)... , Patients with idiopathic pulmonary fibrosis (I... coronary eventsincluding heart attacksthan people...that analyzed the risk of cardiovascular disease i...00 matched controls. , "If you look at them over...ncreased risk of acute coronary syndrome, which is...

(Date:12/4/2008)... , Early detection of lung disease in cystic fibr...nfants, may be the key to controlling the progress...ew research shows that contrary to previous scient...ts can begin as early as infancy even though lung ...We might be able to stop some of the lung function...

(Date:12/4/2008)... NEW DELHI, India, Dec. 5 /PRNewswire-USNewswire/... Organization today launched a global partnership ...afer, accurate and affordable alternatives. , ...he South Asian Conference on Alternatives to Mercu...rganizations and the Indian NGO Toxics Link. , ...

Breaking Medicine News(10 mins):Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2 Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3 Health News:Double threat: Deadly lung disease also linked to heart attacks 2 Health News:Intervention in infants with cystic fibrosis key to slowing progression 2 Health News:Intervention in infants with cystic fibrosis key to slowing progression 3 Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2

[0] Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes [0] Double threat: Deadly lung disease also linked to heart attacks [0] Intervention in infants with cystic fibrosis key to slowing progression [0] Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices

...ave been able to generate human skin tissues, whic...ncer//. The researchers for the study feel that th...enic potential of genes in development of skin can...f skin cancer that results from the cells called m...

...rom University of Liverpool had proposed that pati...efit from medication.// They say that it is advisa...ileptic patients. Researchers of the study feel th...gnificantly benefit the patients in having a bette...

...eating HIV/AIDS patients with highly active antire...f the cardiac risks involved, says researchers fro...can dramatically improve the quality of a HIV/AIDS...specially helpful for patients with advanced HIV-1...

...suffering from head and neck cancer who are underg...edication to fight oropharyngeal candidiasis. Orop... mouth caused by the yeast Candida. This condition... of the disease are the formation of white plaques...

Other Medicine News:

New insight for skin cancer discovered In Early Epilepsy Delay in medications Recommended Need for considering cardiovascular risks before giving HAART for HIV/aids patients Cancer patients can now take once daily medication for infections

(Date:12/4/2008)...e-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq...today announced results from the Company,s recentl...M) (0.09% bromfenac sodium ophthalmic solution) QD...who underwent cataract surgery in two U.S. multi-c...vehicle-controlled studies to evaluate Xibrom 0.09...

(Date:12/4/2008)...swire-FirstCall/ -- Thoratec Corporation,(Nasdaq:...al circulatory support,therapies to save, support...e-specified interim analysis of data from its Hear...hows that patients implanted with the device,achi...in the control group who,were implanted with the ...

(Date:12/4/2008)...swire/ -- Long-term data published in,EuroInterve...Vale Area (MVA),after repair with the MitraClip(R...not associated with clinically significant mitral ...up, none of the patients treated with the,MitraCl... At 12 months no,important differences were repor...

(Date:12/4/2008).../ -- Biopharmaceutical company Kiadis,Pharma anno...atment of the,last patient on its ATIR(TM) phase ... cell based product, is under development to preve...ow early immune reconstitution following a,mismat...ge blood cancer,patients were treated with no cas...

Breaking Medicine Technology:ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 2 ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 3 ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09% 4 Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2 Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3 Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4 Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations 2 The Quest for Americas Life in Beautiful Smiles 3A Captured in Photography 15971 1 The Quest for Americas Life in Beautiful Smiles 3A Captured in Photography 15971 2 The Quest for Americas Life in Beautiful Smiles 3A Captured in Photography 15971 3 VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA 2291 Ongoing Phase 2 Clinical Program 1688 1 VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA 2291 Ongoing Phase 2 Clinical Program 1688 2 VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA 2291 Ongoing Phase 2 Clinical Program 1688 3 VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA 2291 Ongoing Phase 2 Clinical Program 1688 4 Donald W Wyatt Detention Facility Scores 3 Year Accreditation and Among Highest Rated in the United States 15967 1 Donald W Wyatt Detention Facility Scores 3 Year Accreditation and Among Highest Rated in the United States 15967 2 Donald W Wyatt Detention Facility Scores 3 Year Accreditation and Among Highest Rated in the United States 15967 3 International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital 28TM 29 Initiative 4401 1 International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital 28TM 29 Initiative 4401 2 International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital 28TM 29 Initiative 4401 3

[0] ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%[0] Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial [0] Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System [0] Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

...1, 2007--Researchers report that a,variation in a ...isk and that this common variation may be responsi...in white men in the United States.,The research wa...cer Institute (NCI), part of the National Institut...etic Markers of Susceptibility,(CGEMS) initiative....

...INESS WIRE)--Apr 3, 2007 - Calando,Pharmaceuticals...ity-owned subsidiary of Arrowhead Research Corpora...study demonstrating,the anti-proliferative effect ...component of its lead anti-cancer compound, CALAA-...of Ribonucleotide,Reductase Subunit RRM2 Reduce Ce...

Other Medicine Technology:Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 2 Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 3 Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer 4 Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 2 Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 3 Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate 4

Researchers Discover a Common Variation in a Gene Segment that,Increases the Risk for Prostate Cancer Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect,with Lead RNAi Candidate

...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...

Medicine Products:

Cortisol, Serum or Plasma Corticotropin Releasing Hormone Coproporphyrin, Urine Copper, Urine

Drug That Lowers Resting Heart Rate Be...(lar medicine Weill Cornell Medical Colle...),Health